CSIMarket
 


Dermata Therapeutics Inc   (DRMA)
Other Ticker:  
 

Cumulative Dermata Therapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

DRMA's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

DRMA Quick Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 75.98 % -39.05 % -50.03 % 1.3 % -39.17 %
Y / Y Cash & cash equivalent Growth - -17.79 % -20.6 % 7.03 % -42.2 %
Quick Ratio for Trailing Twelve Months Period 5.38 8.07 7.3 6.74 6.65
Total Ranking # # # # #
Seq. Current Liabilities Growth 77.09 % 34.26 % -43.43 % 30.82 % -38.67 %
Seq. Cash & cash equivalent Growth - -21.41 % -3.74 % 40.46 % -22.63 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to jump in Current Liabilities in the IV. Quarter to $2 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 5.38 above Dermata Therapeutics Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry Dermata Therapeutics Inc achieved highest Quick Ratio for Trailing Twelve Months Period. While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about DRMA
Quick Ratio DRMA in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
0 0 0
 




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Immuneering Corporation  14.78 
Ovid Therapeutics Inc   14.63 
Cadrenal Therapeutics Inc   14.33 
Rani Therapeutics Holdings Inc   14.20 
Syndax Pharmaceuticals Inc   14.10 
Ideaya Biosciences Inc   13.57 
Viking Therapeutics Inc   13.33 
Cassava Sciences Inc  13.16 
Scpharmaceuticals Inc   13.05 
Vistagen Therapeutics Inc   12.92 
Nkarta Inc   12.91 
Larimar Therapeutics Inc   12.88 
Olema Pharmaceuticals inc   12.85 
Prothena Corporation Public Limited Company  12.84 
Io Biotech Inc   12.83 
Anaptysbio Inc   12.73 
Lipocine Inc   12.68 
Oric Pharmaceuticals Inc   12.67 
Immutep Limited  12.63 
Crinetics Pharmaceuticals Inc   12.54 
Relmada Therapeutics Inc   12.49 
Atai Life Sciences N v   12.42 
Nanoviricides inc   12.28 
Sensei Biotherapeutics Inc   12.01 
Rapt Therapeutics Inc   11.99 
Compass Pathways Plc  11.81 
Cryoport inc   11.70 
Adicet Bio Inc   11.68 
Kinnate Biopharma Inc   11.66 
Xenetic Biosciences Inc   11.63 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com